Quantcast

Latest cancer therapy Stories

2010-05-26 06:30:00

CALGARY, May 26 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the Cancer Therapy & Research Center at the University of Texas Health Science Center in San Antonio (CTRC) has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with gemcitabine (Gemzar(R)) in patients with advanced pancreatic cancer. The Principal Investigator is Dr. Monica Mita of the CTRC....

2010-03-30 06:30:00

CALGARY, March 30 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the Cancer Therapy & Research Center at the University of Texas Health Science Center (CTRC) has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with carboplatin and paclitaxel in patients with squamous cell carcinoma of the lungs (SCC lung cancer). The Principal Investigator is Dr. Alain C....

2009-11-03 09:04:00

WALTHAM, Mass, Nov. 3 /PRNewswire/ -- On-Q-ity, a next-generation oncology diagnostics company focused on improving cancer therapy effectiveness, announced today that it has closed a $21 million series A financing. The funding was led by MDV-Mohr Davidow Ventures and included Bessemer Venture Partners, Physic Ventures and Northgate Capital. (Logo: http://www.newscom.com/cgi-bin/prnh/20070702/AQM026LOGO) On-Q-ity is developing diagnostics to determine optimal treatment choice for...

2009-10-16 16:31:00

BRIDGEWATER, N.J., Oct. 16 /PRNewswire-FirstCall/ -- Sanofi-aventis U.S. announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Elitek® (rasburicase) to be used for the initial management of plasma uric acid (PUA) levels in adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis syndrome (TLS) and subsequent elevations of plasma uric acid....

2009-10-01 07:00:00

NEW YORK, Oct. 1 /PRNewswire/ -- Released in time for National Breast Cancer Awareness Month, the new documentary Rethinking Cancer presents a compelling look into the therapeutic and psychological journeys of five men and women who chose to use non-toxic, biological therapies to overcome serious illness. Four of the patients featured had been diagnosed with cancers, including breast, lymphatic and bone; and two of these were designated "terminal." Disease-free from 15 - 37 years, they are...

2009-09-24 06:30:00

CALGARY, Sept. 24 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the Cancer Therapy Research Center at the University of Texas Health Science Center (CTRC) has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with metastatic melanoma. The Principal Investigator is Dr. Devalingam Mahalingam, M.D., Ph.D., MRCP(UK),...

2009-07-30 07:00:00

WILMINGTON, Del., July 30 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced the company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) and a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) for an investigational drug, vandetanib 100 mg for use in combination with chemotherapy for the treatment of advanced non-small cell lung cancer in patients previously treated with one prior anti-cancer therapy. The...

2009-06-18 14:53:29

Chemists at the University of California-Santa Cruz say they've developed novel compounds that show promise for photodynamic cancer therapy. The compounds, called dye-sensitized ruthenium nitrosyls, are absorbed by cancer cells and respond to specific wavelengths of light by releasing nitric oxide, which triggers the cancer cells' death, the researchers said. For cancer treatment, you want localized delivery of a very high concentration of nitric oxide, said Professor Pradip Mascharak. We've...

2009-03-31 04:00:00

DOYLESTOWN, Pennsylvania and OXFORD, England, March 31 /PRNewswire/ -- EUSA Pharma Inc ('EUSA'), a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, announced today the successful completion of its European launch of CAPHOSOL(R) for the prevention and treatment of oral mucositis associated with cancer therapy, as an adjunct to standard oral care. CAPHOSOL is also indicated for hyposalivation and xerostomia (dryness of the mouth or throat)...

2009-02-17 06:50:00

LONDON, Feb. 17 /PRNewswire/ -- Cancer may well surpass cardiovascular diseases as the primary case of death in Europe by 2012. To prevent this from happening, cancer therapeutics have to shift in focus from the treatment of symptoms to offering a total cure, despite the complex, multifactorial nature of cancer indications. (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO) "As cancer spreads rapidly through Europe, therapy developers are looking to improve the cancer...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related